NICE final guidance backs Angelini's Ontozry for focal-onset seizures

16 December 2021
angelini_big

The UK’s National Institute of Heath and Care Excellence (NICE) has published its final technology appraisal guidance (TAG) for Ontozry (cenobamate), a treatment for focal onset seizures in uncontrolled epilepsy from Arvelle Therapeutics, a unit of privately-held Italian drugmaker Angelini Pharma.

Cenobamate is recommended as an option for treating focal onset seizures with or without secondary generalized seizures in adults with drug-resistant epilepsy that has not been adequately controlled with at least two antiseizure medicines. It is recommended only if it is used as an add-on treatment, after at least one other add-on treatment has not controlled seizures, and treatment is started in a tertiary epilepsy service.

Epilepsy is a serious condition that affects one in 100 people in the UK and only 52% of those with condition are seizure free. People with uncontrolled seizures are more likely to experience co-morbidities, social stigmatization and poor quality of life.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical